As heart failure with reduced ejection fraction is the most severe form of HF, the availability of innovative drugs like sacubitril/valsartan that reduced both mortality and hospitalization for HF was an attractive therapeutic alternative to standard care with ACE inhibitors or ARBs and currently recommended therapeutic option in clinical practice guidelines worldwide. Here, ACE is linked to heart failure.